Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers
Volak LP, Hanley MJ, Masse G, Hazarika S
Published in British Journal of Clinical Pharmacology
Methodology
Randomized, placebo-controlled six-way crossover study; curcuminoids 4 g plus piperine 24 mg dosed four times over 2 days before probe drugs midazolam (CYP3A), flurbiprofen (CYP2C9) and paracetamol (UGT/SULT)
Key Findings
Despite in vitro inhibition signals, the curcuminoid/piperine preparation produced no clinically important change in midazolam or flurbiprofen pharmacokinetics in healthy volunteers.
Conclusions
Short-term high-dose curcumin with piperine does not meaningfully inhibit phase I CYP3A or CYP2C9 activity in humans.
Limitations
Very small sample (n=8), short dosing period, healthy young volunteers only.
Supplements Studied
Compared with placebo, the curcuminoid/piperine preparation had no clinically important effect on midazolam or flurbiprofen pharmacokinetics.
Turmeric extract derived curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin) are currently being evaluated for the treatment of cancer and Alzheimer's dementia.
Outcomes Measured
Compared with placebo, the curcuminoid/piperine preparation had no clinically important effect on midazolam or flurbiprofen pharmacokinetics.
Study Details
Access Study
Disclosures
Funding
NIH
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.